$1.10+0.01 (+0.92%)
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Inovio Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.10. Wall Street consensus targets $5.86 (5 analysts), implying a +432.7% move over the next 12 months. The stock is currently near its 52-week low of $1.03, remaining 39.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases...
Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending Dec. 31,
The study showed that the treatment helped reverse precancerous changes in the cervix and clear the high-risk HPV virus that causes them in many patients.
Moby summary of Inovio Pharmaceuticals, Inc.'s Q1 2026 earnings call
Inovio Pharmaceuticals Inc (INO) reports significant strides in regulatory progress and commercial preparations, despite financial hurdles and competitive pressures.
Inovio Pharmaceuticals (NASDAQ:INO) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://app.webinar.net/LJpjgyEg2Oa Summary Inovio Pharmaceuticals Inc reported a net loss of $19.7 million for Q1 2026, with operating ex